Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Frommherz LH, Schempp CM, Has C. Br J Dermatol 2021;184:770-772.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Frommherz LH, Schempp CM, Has C. Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency. Br J Dermatol 2021;184:770-772.
PMID: 33205394